TAF 被FDA批准上市了！

csn1

logitech02 发表于 2016-11-11 08:55
恭喜美帝战友.国内的继续吃,直到肾脏透析

恩替的副作用怎么样？帮忙分析下

REMEMBERFORGET

hbvgo 发表于 2016-11-11 15:17
Vemlidy will be available next week at a price of $997.77 for a 30-tablet bottle

一盒6000多人民币，一年7万多人民币，这药还是贵！
卖到中国，价格也许更贵，能吃得起的人不多。
而且是长期吃的药，不是治愈药。
不划算！

hbvgo

回复 REMEMBERFORGET 的帖子

Gilead的药物都是分地区定价的，在中国的定价预计仍在1000--2000之间。就好像viread在美国卖1000美元左右，但是在非洲viread300美元就能买一年药了。和viread不同，2015年秋天，gilead的合作方gsk已经在中国大陆开始了Vemlidy的注册工作，这意味着TAF很快会在中国获批，而不像viread那样要晚上6,7年。另外，也与viread不同，TAF的MPP协议包含中国大陆，言下之意，gilead允许大陆厂商在分割适当利润的情况下仿制，价格自然不可能定的太高。

齐欢畅2

回复 hbvgo 的帖子

点赞。

齐欢畅2

回复 hbvgo 的帖子

同一药物不同的定价是有的，但估计taf的价格在中国也不会很便宜，至少一千五左右一个月吧。我估计，上市还需要一段时间吧，看到华山医院有三期试验，中国上市还需要等一段时间。

kite2002005

回复 齐欢畅2 的帖子

1500就买了

齐欢畅2

估计的，我自己。

齐欢畅2

Gilead has also established licensing agreements with 19 generic drug manufacturers in India, South Africa and China, as well as the Medicines Patent Pool, granting them rights to produce and sell high-quality, low-cost generic versions of Gilead HBV medicines in 112 developing countries. Vemlidy is already an integrated component of the company’s generic licensing agreements, and with FDA approval, manufacturing partners may begin production and distribution of a generic version of this medicine.
各国定价不同的。上市不远了。

dapang

2000元每月的价格接受

轻风飞扬

Adverse Reactions

Most common adverse reactions (incidence ≥5%; all grades) were headache, abdominal pain, fatigue, cough, nausea and back pain.

Drug Interactions

Coadministration of VEMLIDY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of tenofovir and the risk of adverse reactions.
Coadministration of VEMLIDY is not recommended with the following:  oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, or St. John’s wort. Such coadministration is expected to decrease the concentration of tenofovir alafenamide, reducing the therapeutic effect of VEMLIDY. Drugs that strongly affect P-gp and BCRP activity may lead to changes in VEMLIDY absorption.
Consult the full prescribing information for VEMLIDY for more information on potentially significant drug interactions, including clinical comments.

Dosage and Administration

Dosage: Adults; 1 tablet taken once daily with food.
Renal Impairment: Not recommended in patients with CrCl <15 mL/min.
Hepatic Impairment: Not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment.
Testing prior to initiation: HIV infection.

还有是有一定副作用，但肾损和骨损比替诺福韦小